Zilebesiran

RNA / oligonucleotide

Also known as RG6615

Phase 3underway

Evidence outlook · registrational

Hypertension: registrational readout pending

Entered Phase 3 on reliable signal mid-stage evidence. Registrational readout expected around 2030-09-23. The sponsor reported topline results of a Phase 2 study on 2025-08-30 (KARDIA-3 (zilebesiran add-on) did not meet its pre-specified significance definition); that is not the registrational readout.

KARDIA-1 (NCT04936035): The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Hypertension
Phase 2 (3)
Hypertension
NCT06272487 · Alnylam Pharmaceuticals
2024-02-29 – 2025-12-01 · High Cardiovascular Risk, Hypertension
What this study did
NCT05103332 · Alnylam Pharmaceuticals
2021-11-05 – 2024-09-13 · Hypertension
What this study did
Phase 1/2 (1)
Hypertension
NCT06423352 · Alnylam Pharmaceuticals
2024-06-05 – 2025-07-17 · Mild to Moderate Hypertension
What this study did
Phase 1 (2)
Hypertension
NCT03934307 · Alnylam Pharmaceuticals
2019-05-01 – 2023-01-04 · Hypertension
What this study did
Other / comorbidity
NCT06675565 · Alnylam Pharmaceuticals
2024-11-05 – 2025-09-08 · Healthy Volunteers
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Hypertension
NCT07553442 · Alnylam Pharmaceuticals
2026-04-27 – 2028-10-01 · Hypertension
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hypertension: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zilebesiran: this drugPhase 3RNA / oligonucleotideAngiotensinogen (AGT)Reliable signal
NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M)
Aprocitentan (Tryvio)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Reliable signal
NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046).
Baxdrostat (Baxfendy)ApprovedSmall moleculeAldosterone synthase (CYP11B2)Reliable signal
NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001).
NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1)
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
AD-209Phase 3Small moleculeAngiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporterPartial signal
NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20).
AGSAVIPhase 3Small moleculeAngiotensin II receptor / Calcium channel / Thiazide-like diureticPartial signalNo reviewed efficacy summary in this indication
Amlodipine / Valsartan / Rosuvastatin (CJ-30060)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
Esaxerenone (Minnebro)Phase 3Small moleculeMineralocorticoid receptorPartial signal
NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52
NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
Levamlodipine / Valsartan (SYH9056)Phase 3Small moleculeAngiotensin II type 1 receptor / L-type calcium channel (dual)Partial signal
NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16).
LorundrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Reliable signal
NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001)
NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm)
Olmesartan / Rosuvastatin (DWJ1276) (Olostar)Phase 3Small moleculeAngiotensin II receptor / HMG-CoA reductasePartial signal
NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
QR12000Phase 3Small moleculeAT1R; neprilysinPartial signalNo reviewed efficacy summary in this indication
Sacubitril / Valsartan (Entresto)Phase 3Small moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001).
NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SAL0120Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
Valsartan / Amlodipine / Chlorthalidone (AJU-C52)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / Thiazide-like diureticReliable signal
NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control)
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
HRS-9563Phase 2RNA / oligonucleotideAGT (angiotensinogen) mRNAnot yet gradedNo reviewed efficacy summary in this indication
IBI3016Phase 2RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
QCZ484Phase 2RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
QLS1410Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
RTN-001Phase 2Small moleculePDE5not yet gradedNo reviewed efficacy summary in this indication
SAL0140Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
TonlamarsenPhase 2RNA / oligonucleotideAngiotensinogen (AGT)Partial signal
NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed.
NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg)
VB19055Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
BEBT-701Phase 1/2RNA / oligonucleotideAngiotensinogen (AGT) / PCSK9 (dual)not yet gradedNo reviewed efficacy summary in this indication
ADX-850Phase 1RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
Carvedilol (CKD-385)Phase 1Small moleculeBeta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist)Partial signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
HS-10522Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JX09Phase 1Small moleculeAldosterone synthase (CYP11B2)Partial signalNo reviewed efficacy summary in this indication
KK3910Phase 1Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
KN060Phase 1Monoclonal antibodyFactor XI/XIa (FXI/FXIa)not yet gradedNo reviewed efficacy summary in this indication
LivaloV
Phase 1(overall)
Small moleculeHMG-CoA reductase / Angiotensin II type 1 receptornot yet gradedNo reviewed efficacy summary in this indication
Long-Acting ANP Analog (LY3971297)Phase 1PeptideNatriuretic peptide receptor (NPR-A)not yet gradedNo reviewed efficacy summary in this indication
NurandociguatPhase 1Small moleculeSoluble guanylate cyclaseWeak signalNo reviewed efficacy summary in this indication
SHR-4658
Phase 1(overall)
Peptide—not yet gradedNo reviewed efficacy summary in this indication
C2402
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Candesartan / Amlodipine
—(overall)
Small moleculeAngiotensin II type 1 receptor / L-type calcium channelnot yet gradedNo reviewed efficacy summary in this indication
DehydraTECH-CBD
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Lercanidipine
—(overall)
Small moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
OLOMAX
—(overall)
Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Rosuampin
—(overall)
Small moleculeHMG-CoA reductase / Calcium channelnot yet gradedNo reviewed efficacy summary in this indication
N0877DiscontinuedSmall moleculeAngiotensin II receptor / Thiazide diureticnot yet gradedNo reviewed efficacy summary in this indication
SER-100DiscontinuedPeptideORL-1 (nociceptin opioid-like receptor)Weak signalFeatured results are safety only in this race

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zilebesiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
September 2030 (1)
Phase 3HypertensionRecruiting
Est. primary completion 2030-09-23 · NCT07181109 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 August 2025Topline resultKARDIA-3 (zilebesiran add-on) did not meet its pre-specified significance definition
Roche; Alnylam · Source ↗